CMS Asks AMA For Help In Comparative Research; "Non-Burdensome" Studies Will Be Key, McClellan Says
This article was originally published in The Pink Sheet Daily
"The first thing we need to do is develop evidence on what works and what doesn't for seniors," McClellan tells AMA. "We can do better."
You may also be interested in...
US FDA’s workshop to discuss new ideas to assess the impact of the opioid REMS comes after the industry collaboration behind the REMS has deemed the task essentially impossible.
Whether CME for pain management has the intended impact on prescribing is likely focus of new ‘suite of studies’ intended to assess the opioid REMS program. The challenges for FDA include teasing out the impact of the risk management program amid all the other public health efforts on opioids.
FDA has approved over 50 new molecular entities in a year for the second time – a truly remarkable job amid a global pandemic. But will 2021 be a tougher year?